Summit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy Community
OXFORD, United Kingdom, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, today …